Additionally, increased histone deacetylase (HDAC) activity has been associated with resistance, while HDAC inhibitors can restore BRCA1 expression, thereby enhancing tumor sensitivity to PARP inhibitors. This evidence concerns the gene PARP1 and neoplasm.